Boston Scientific Co. (NYSE:BSX) Shares Sold by Prudent Man Advisors LLC

Prudent Man Advisors LLC trimmed its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 23.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,963 shares of the medical equipment provider’s stock after selling 3,328 shares during the period. Prudent Man Advisors LLC’s holdings in Boston Scientific were worth $919,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Swiss National Bank raised its stake in Boston Scientific by 0.3% during the third quarter. Swiss National Bank now owns 4,363,600 shares of the medical equipment provider’s stock worth $365,670,000 after acquiring an additional 11,600 shares during the period. Thrivent Financial for Lutherans raised its position in shares of Boston Scientific by 9.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 366,807 shares of the medical equipment provider’s stock worth $30,740,000 after purchasing an additional 32,844 shares during the period. RiverPark Advisors LLC raised its position in shares of Boston Scientific by 49.1% during the 3rd quarter. RiverPark Advisors LLC now owns 653 shares of the medical equipment provider’s stock worth $55,000 after purchasing an additional 215 shares during the period. Adero Partners LLC boosted its position in Boston Scientific by 3.6% during the 3rd quarter. Adero Partners LLC now owns 3,617 shares of the medical equipment provider’s stock valued at $303,000 after purchasing an additional 127 shares during the period. Finally, Atlanta Consulting Group Advisors LLC grew its stake in Boston Scientific by 17.4% during the 3rd quarter. Atlanta Consulting Group Advisors LLC now owns 3,757 shares of the medical equipment provider’s stock worth $315,000 after buying an additional 557 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the transaction, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. This represents a 45.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the sale, the executive vice president now directly owns 34,748 shares of the company’s stock, valued at approximately $2,913,967.28. The trade was a 16.73 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 309,270 shares of company stock worth $26,196,718. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $86.99 on Monday. The business’s 50-day moving average is $85.26 and its 200-day moving average is $79.59. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The company has a market capitalization of $128.21 billion, a price-to-earnings ratio of 71.89, a P/E/G ratio of 2.56 and a beta of 0.79. Boston Scientific Co. has a fifty-two week low of $53.56 and a fifty-two week high of $89.30.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.50 EPS. Equities research analysts expect that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the subject of several recent research reports. Barclays upped their price target on shares of Boston Scientific from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Thursday, August 22nd. Sanford C. Bernstein raised their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Wells Fargo & Company upped their price objective on Boston Scientific from $87.00 to $98.00 and gave the company an “overweight” rating in a report on Thursday, October 24th. Morgan Stanley upped their price target on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a report on Thursday, October 24th. Finally, Evercore ISI lifted their price objective on shares of Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Four analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.